Preoperative assessment with expression of p53 and Foxp4 of malignancy for endometrial cancer of uterine corpus

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18666
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Kanazawa University
• Principal Investigator: Orisaka Shunsuke 金沢大学, 附属病院, 医員 (20724173)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: p53 / Foxp4 / 子宮体部類内膜癌 / リンパ節転移 / 再発

Outline of Final Research Achievements

We showed the expression of p53 and Foxp4 by immunohistochemistry of tissue sample in patients with regional lymph node metastasis and/or postoperative disease recurrence who had undergone hysterectomy as a primary surgical therapy for endometrial cancer. Therefore, immunohistochemistry outcome of p53 and Foxp4 may be useful parameter of the therapeutic principle. We performed immunohistochemistry for expression of p53 and Foxp4 by the endometrial biopsy tissues for diagnosis.
There were the cases which the surgical specimen and the biopsy tissues did not match with immunohistochemistry for expression of p53 and Foxp4. We investigated the difference of them. Although many tissue samples were experimented about the difference between the surgical specimen and the biopsy tissues, it did not match.
Therefore, it was difficult to preoperative assessment of the therapeutic principle from immunohistochemistry for expression of p53 and Foxp4 by biopsy tissue.

Free Research Field

婦人科悪性腫瘍

Academic Significance and Societal Importance of the Research Achievements

子宮内膜癌症例のリンパ節転移・術後再発症例にp53およびFoxp4の発現が認められ、これらのパラメーターが術前診断に応用できれば、悪性度の術前評価精度を向上させる新しい検査法を提案できると考えられた。
しかし、今回の結果では術前採取した内膜組織と手術検体のp53とFoxp4の免疫組織染色結果が一致しない症例が確認され、手術検体と術前検体は同様の結果にはならなかった。
したがって、今回の結果からは新しい検査法を提案できないが、p53およびFoxp4発現がリンパ節転移・術後再発に関与している可能性はあるため今後更なる検討を行っていく必要がある。